Hoth Therapeutics Stock Performance
| HOTH Stock | USD 1.03 0.05 5.10% |
The company retains a Market Volatility (i.e., Beta) of 1.6, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Hoth Therapeutics will likely underperform. At this point, Hoth Therapeutics has a negative expected return of -0.22%. Please make sure to check out Hoth Therapeutics' maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and market facilitation index , to decide if Hoth Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Hoth Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Last Split Factor 1:25 | Last Split Date 2022-10-26 |
1 | Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities | 11/20/2025 |
2 | Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metaboli... | 12/03/2025 |
3 | Published on 2025-12-10 005710 - B NI V | 12/09/2025 |
4 | Insider Trading | 12/19/2025 |
5 | Acquisition by Springer Graig of 25000 shares of Hoth Therapeutics at 0.7548 subject to Rule 16b-3 | 01/09/2026 |
6 | Hoth Therapeutics highlights obesity and pipeline progress to regulators - TipRanks | 01/16/2026 |
7 | Hoth Therapeutics Delivers 100 percent Clinical Response with 50 percent Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients | 01/22/2026 |
8 | Acquisition by Robb Knie of 800000 shares of Hoth Therapeutics subject to Rule 16b-3 | 01/30/2026 |
9 | Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets | 02/05/2026 |
10 | Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases | 02/12/2026 |
Hoth Therapeutics Relative Risk vs. Return Landscape
If you would invest 117.00 in Hoth Therapeutics on November 15, 2025 and sell it today you would lose (19.00) from holding Hoth Therapeutics or give up 16.24% of portfolio value over 90 days. Hoth Therapeutics is currently does not generate positive expected returns and assumes 3.8022% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Hoth, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Hoth Therapeutics Target Price Odds to finish over Current Price
The tendency of Hoth Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.03 | 90 days | 1.03 | about 63.06 |
Based on a normal probability distribution, the odds of Hoth Therapeutics to move above the current price in 90 days from now is about 63.06 (This Hoth Therapeutics probability density function shows the probability of Hoth Stock to fall within a particular range of prices over 90 days) .
Hoth Therapeutics Price Density |
| Price |
Predictive Modules for Hoth Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Hoth Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Hoth Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hoth Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Hoth Therapeutics is not an exception. The market had few large corrections towards the Hoth Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Hoth Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Hoth Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.4 | |
β | Beta against Dow Jones | 1.60 | |
σ | Overall volatility | 0.12 | |
Ir | Information ratio | -0.09 |
Hoth Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Hoth Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Hoth Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Hoth Therapeutics generated a negative expected return over the last 90 days | |
| Hoth Therapeutics has some characteristics of a very speculative penny stock | |
| Hoth Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (8.19 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Hoth Therapeutics currently holds about 11.62 M in cash with (6.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Hoth Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases |
Hoth Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Hoth Stock often depends not only on the future outlook of the current and potential Hoth Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Hoth Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 6.4 M | |
| Cash And Short Term Investments | 7 M |
Hoth Therapeutics Fundamentals Growth
Hoth Stock prices reflect investors' perceptions of the future prospects and financial health of Hoth Therapeutics, and Hoth Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Hoth Stock performance.
| Return On Equity | -1.51 | ||||
| Return On Asset | -0.84 | ||||
| Current Valuation | 6.71 M | ||||
| Shares Outstanding | 15.51 M | ||||
| Price To Earning | (7.16) X | ||||
| Price To Book | 1.77 X | ||||
| EBITDA | 27.13 K | ||||
| Net Income | (8.19 M) | ||||
| Cash And Equivalents | 11.62 M | ||||
| Cash Per Share | 9.02 X | ||||
| Total Debt | 31.07 K | ||||
| Debt To Equity | 2.01 % | ||||
| Current Ratio | 15.74 X | ||||
| Book Value Per Share | 0.54 X | ||||
| Cash Flow From Operations | (6.98 M) | ||||
| Earnings Per Share | (1.02) X | ||||
| Market Capitalization | 14.46 M | ||||
| Total Asset | 7.71 M | ||||
| Retained Earnings | (60.41 M) | ||||
| Working Capital | 6.81 M | ||||
| Current Asset | 448.84 K | ||||
| Current Liabilities | 312.22 K | ||||
About Hoth Therapeutics Performance
By evaluating Hoth Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Hoth Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Hoth Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Hoth Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.96) | (1.00) | |
| Return On Capital Employed | (1.07) | (1.13) | |
| Return On Assets | (0.96) | (1.00) | |
| Return On Equity | (1.07) | (1.12) |
Things to note about Hoth Therapeutics performance evaluation
Checking the ongoing alerts about Hoth Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Hoth Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Hoth Therapeutics generated a negative expected return over the last 90 days | |
| Hoth Therapeutics has some characteristics of a very speculative penny stock | |
| Hoth Therapeutics has high historical volatility and very poor performance | |
| Net Loss for the year was (8.19 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Hoth Therapeutics currently holds about 11.62 M in cash with (6.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Hoth Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases |
- Analyzing Hoth Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Hoth Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Hoth Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Hoth Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Hoth Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Hoth Therapeutics' stock. These opinions can provide insight into Hoth Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Hoth Stock analysis
When running Hoth Therapeutics' price analysis, check to measure Hoth Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hoth Therapeutics is operating at the current time. Most of Hoth Therapeutics' value examination focuses on studying past and present price action to predict the probability of Hoth Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hoth Therapeutics' price. Additionally, you may evaluate how the addition of Hoth Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |